Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dacomitinib monotherapy in advanced unresectable or metastatic cutaneous squamous cell carcinoma
2014-002175-28Phase 2Completed
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Jun 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dacomitinib in cutaneous squamous cell carcinoma (cSCC), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Objective response rate. Started Jun 2014; status: completed.
02
Drugs
dacomitinib
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on 2014-002175-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002175-28.